CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
https://doi.org/10.15829/1560-4071-2018-3-49-53
Abstract
Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.
Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of clopidogrel on platelet reactivity was identified through examination of PRU values using VerifyNow® with a cut-off point of 208. From the PRU values, it can be classified whether patients were resistant or responsive.
Results. This study shows that 30 patients with ACS who received clopidogrel, 24 patients (80%) were male and 6 female patients (20%). Hypertension was the greatest risk factor for the coronary arterial disease. A total of 11 patients (36,77%) were resistant and 19 patients (63,33%) were responsive to clopidogrel. About 46,67% patients were extensive metabolizers. PRU of these patients were lower than intermediate and poor metabolizers.
Conclusion. ACS patients with functional loss of CYP2C19 activity have lower platelet activity when treated with clopidogrel. Routine CYP2C19 and PRU testing may be warranted. Further research is needed with a larger number of patients to investigate the pharmacogenetic profile of CYP2C19 and the cause of clopidogrel resistance in Minang patients.
About the Authors
R. Rahmatini
Andalas University.
Indonesia
Indonesia
Department of Pharmacology and Therapeutic, Faculty of Medicine.
Padang.
G. Aliska
Andalas University.
Indonesia
Indonesia
Department of Pharmacology and Therapeutic, Faculty of Medicine.
Padang.
M. Syafri
Dr. M. Djamil Hospital ; Andalas University.
Indonesia
Indonesia
Department of Cardiology and Vascular Medicine Dr. M. Djamil Hospital ; Faculty of Medicine, Andalas University.
Padang.
A. Achyar
Andalas University.
Indonesia
Indonesia
Biomedical Laboratory, Faculty of Medicine.
Padang.
References
1. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res 2014; 114 (12): 1959-75.
2. Melati R, Basuki E, Setianto B. Relationship between job strain and myocardial infarction in the national cardiovascular patient center. J Kardiol Ind 2008; 29 (1): 12-9.
3. Ogawa H, Isshiki T, Kimura T, et al. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. J Cardiol 2016; 68 (1): 29-36.
4. González A, Moniche F, Cayuela A, et al. Effect of CYP2C19 polymorphisms on the platelet response to clopidogrel and influence on the effect of high versus standard dose clopidogrel in carotid artery stenting. Eur J Vasc Endovasc Surg 2016; 51 (2): 175-86.
5. Rehman KU, Akhtar T, Sabar MF, et al. Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. Exp Ther Med 2015; 10 (1): 309-15.
6. Hersberger M, Marti-Jaun J, Rentsch K, et al. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase. Clin Chem 2001; 47 (4): 772-4.
7. Sukasem C, Tunthong R, Chamnanphon M, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenomics Pers Med 2013; 6: 85-91.
8. Indonesian Heart Association. Pedoman tatalaksana sindrome koroner akut. Centra Communications; 2015. p.11-35.
9. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart Journal 2011; 32 (23): 2999-3054.
10. Zehnder JL. Drugs used in disorders of coagulation. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic & Clinical Pharmacology. 11th ed. Singapore: McGraw-Hill, 2009: p.598-99.
11. Subraja K, Dkhar SA, Priyadharsini R, et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol 2013; 69 (3): 415-22.
12. Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. Yonsei Med Journal 2011; 52 (5): 734-8.
13. Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium. clinical pharmacogenetics consortium implementation guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94 (3): 317-23.
Review
For citations:
Rahmatini R., Aliska G., Syafri M., Achyar A. CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS. Russian Journal of Cardiology. 2018;(3):49-53. https://doi.org/10.15829/1560-4071-2018-3-49-53
Views:
1018
Email this article 